Our mission is to leverage our proprietary OrbiSeq™ technology platform for early disease detection, treatment and prevention of complex diseases.
Our game-changing OrbiSeq™ technology platform analyzes repetitive DNA which uniquely reflects both inherited and acquired disease risk.
For more information on our products and services, or if you would like copies of our publications, please contact us.
Transforming complex disease diagnosis, treatment, and prevention through Early Warning Genomics
Orbit Genomics
Since the first sequencing of the human genome in 2003, tremendous gains have been made in understanding hereditary cancer syndromes, with over 50 having been identified. Genetic tests to assess a person’s inherited risk of developing certain cancers are abundant. However, the tests are not clinically actionable for most healthy people. Genetic mutations measure population risk, not individual risk. Genetic mutations (SNPs) identify increased disease risk, but their presence doesn’t guarantee disease will occur, and their absence doesn’t guarantee disease will not occur. Complex diseases are caused by a combination of genetic mutations and environmental factors, including lifestyle. Orbit Genomics’ proprietary OrbiSeq technology platform analyzes a different part of your DNA that uniquely reflects both inherited predisposition to disease and the risk you’ve acquired from from living. We analyze your DNA’s early warning system.
News
-
Orbit Genomics Named As Finalist In 2024 Pepperdine Most Fundable Companies Competition
Orbit Genomics, Inc. has been named one of the 30 finalists for the Pepperdine Most Fundable Companies Competition, chosen from over 2,300 applicants. We would like to thank Pepperdine and the judges for this competition in recognizing the company for its efforts in developing highly accurate genomics tests for oncology, cardiovascular, longevity and other indications.…
-
Orbit Genomics, Inc. was awarded a two-year, $2million Direct to Phase II SBIR Grant from NIH/NCI to develop a subtyping lung cancer blood test
Orbit Genomics was awarded a two-year $2MM Direct to Phase II SBIR Grant from NIH/NCI to develop the second-generation of our lung cancer test, OrbiSeq-L. OrbiSeq-L, is a simple blood test that diagnoses lung cancer in patients that have low-dose CT scans with indeterminate pulmonary nodules, IPNs. Every year, 2.5-3 million Americans have low-dose CT…